Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+lymphoid malignancies

Authors :: Frigault, Matthew J.
Graham, Charlotte E.
Berger, Trisha R.
Ritchey, Julie
Horick, Nora K.
El-Jawahri, Areej
Scarfò, Irene
Schmidts, Andrea
Haradhvala, Nicholas J.
Wehrli, Marc
Lee, Won-Ho
Parker, Aiyana L.
Wiggin, Hadley R.
Bouffard, Amanda
Dey, Aonkon
Leick, Mark B.
Katsis, Katelin
Elder, Eva L.
Dolaher, Maria A.
Cook, Daniella T.
Chekmasova, Alena A.
Huang, Lu
Nikiforow, Sarah
Daley, Heather
Ritz, Jerome
Armant, Myriam
Preffer, Fred
DiPersio, John F.
Nardi, Valentina
Chen, Yi-Bin
Gallagher, Kathleen M. E.
Maus, Marcela V.
Source :: Blood; September 2024, Vol. 144 Issue: 11 p1153-1167, 15p
Publication Year :: 2024
Abstract: •CAR-37 T cells expanded to >98% of T cells and led to complete responses but caused severe cytopenia associated with high levels of IL-18.•Depleting CAR-37 T cells using cetuximab to target the safety switch was unsuccessful in the setting of neutropenia.

Full Text Access

Tools